Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides

Talpur, Rakhshandra; Demierre, M.; Geskin, Larisa J.; Baron, Elma D.; Pugliese, Silvina; Eubank, Kelley V.; Zic, John A.; Miller, Donald R.; Tharp, Michael D.; Bohjanen, Kimberly; Duvic, Madeleine

doi:10.1016/j.clml.2011.03.003

Cited by 42 publications

(36 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, quality-of-life measurements indicated an improvement in emotional scores over time. 52 Current National Comprehensive Cancer Network (NCCN) guidelines for non-Hodgkin lymphoma (NHL) (Version 5.2014) do not recommend ECP as primary treatment in early stage MF (IA, IB, IIA). However, in patients with stage IA, IB, and IIA disease and B1 blood involvement or those with treatment refractory disease, ECP is listed as a systemic treatment option along with retinoids, IFNs, histone deacetylase inhibitors, and methotrexate.…”

Section: Early Stage Mycosis Fungoidesmentioning

confidence: 99%

“…52 The UVAR XTS Photopheresis System (Therakos, Inc Raritan, NJ) was used to administer ECP for 2 consecutive days once monthly for 12 months. Patients who did not respond after 6 months of ECP were treated adjunctively with oral bexarotene (150 mg/m 2 ) alone or combined with interferon (IFN) alfa (1-3 million units 3 times per week).…”

Section: Early Stage Mycosis Fungoidesmentioning

confidence: 99%

See 1 more Smart Citation

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Zic

2015

Dermatologic Clinics

Self Cite

View full text Add to dashboard Cite

Extracorporeal photopheresis (ECP) is an immunomodulating procedure that leads to an expansion of peripheral blood dendritic cell populations and an enhanced TH1 immune response in cutaneous T-cell lymphoma (CTCL). Because of its excellent side effect profile and moderate efficacy, ECP is considered first-line therapy for erythrodermic mycosis fungoides (MF) and Sézary syndrome. Patients with a measurable but low blood tumor burden are most likely to respond to ECP, and the addition of adjunctive immunostimulatory agents may also increase response rates. There may be a role for ECP in the treatment of refractory early stage MF, but data are limited.

show abstract

Section: Early Stage Mycosis Fungoidesmentioning

confidence: 99%

Section: Early Stage Mycosis Fungoidesmentioning

confidence: 99%

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Zic

2015

Dermatologic Clinics

Self Cite

View full text Add to dashboard Cite

show abstract

“…A multicenter, prospective study has extended this evidence [5]. In this study, 19 patients with stages IA-IIA (T1 or T2) mycosis fungoides were treated with ECP.…”

Section: Extracorporeal Photopheresis For the Treatment Of Cutaneous mentioning

confidence: 91%

“…In guidelines issued in the United Kingdom in 2003, ECP was recommended for advanced stages of CTCL, particularly after skin-directed therapies fail [2]. This modality is now also being actively investigated for primary treatment in earlier stages because the low risk of adverse events makes it attractive for slowing disease progression even in very indolent forms of CTCL [5]. This modality is now also being actively investigated for primary treatment in earlier stages because the low risk of adverse events makes it attractive for slowing disease progression even in very indolent forms of CTCL [5].…”

Section: Introductionmentioning

confidence: 99%

“…(1) Cutaneous T-cell and natural killer (NK)cell lymphomas (2) Mycosis fungoides (3) Mycosis fungoides variants and subtypes (a) Folliculotropic mycosis fungoides (b) Pagetoid reticulosis (c) Granulomatous slack skin (4) Sézary syndrome (5) Adult T-cell leukemia/lymphoma (6) Primary cutaneous CD30þ lymphoproliferative disorders (a) Primary cutaneous anaplastic large cell lymphoma (b) Lymphomatoid papulosis (7) Subcutaneous panniculitis-like T-cell lymphoma (8) Extranodal NK/T-cell lymphoma, nasal type (9) Primary cutaneous peripheral T-cell lymphoma, unspecified (10) Primary cutaneous aggressive epidermotropic…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Photopheresis in the treatment of cutaneous T-cell lymphoma

Zic

2012

Oncology Times

Self Cite

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma is the overall name for a group of malignancies in which malignant T-lymphocytes localize at the skin. Of the current 20 recognized subtypes of the disease, the most common are mycosis fungoides and Sézary syndrome. Extracorporeal photopheresis (ECP), an immunomodulating procedure that treats pheresed blood with a photoactive agent, received US Food and Drug Administration approval in 1988 as a medical device for the treatment of CTCL patients, one of many treatment options for such patients. This was followed in 2003 by guidelines in the United Kingdom that recommended ECP for patients with advanced CTCL, particularly after skin-directed treatment options have failed. ECP is now under investigation for use in patients with earlier stages of CTCL. This article reviews the evolution of the ECP technique -for example, the most recent generation of the device requires a lower extracorporeal volume of blood than the previous version did, thus making it possible for more patients to be candidates for the procedure. In addition, there has been progress in understanding how ECP works at the cellular level.

show abstract

Primary Cutaneous T‐cell Lymphoma

Child

Whittaker

2014

Evidence‐Based Dermatology

View full text Add to dashboard Cite

Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides

Cited by 42 publications

References 52 publications

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

Photopheresis in the treatment of cutaneous T-cell lymphoma

Primary Cutaneous T‐cell Lymphoma

Contact Info

Product

Resources

About